JP2013519653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519653A5 JP2013519653A5 JP2012552401A JP2012552401A JP2013519653A5 JP 2013519653 A5 JP2013519653 A5 JP 2013519653A5 JP 2012552401 A JP2012552401 A JP 2012552401A JP 2012552401 A JP2012552401 A JP 2012552401A JP 2013519653 A5 JP2013519653 A5 JP 2013519653A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- scb
- derivatives
- gtx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125794 sodium channel blocker Drugs 0.000 claims description 15
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 15
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims description 7
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims description 6
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 5
- 229950010357 tetrodotoxin Drugs 0.000 claims description 5
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- CDJDGQRYHDBSKC-UHFFFAOYSA-N 2,3,4,5,6,7,8,9-octahydro-1h-purine Chemical compound C1NCNC2NCNC21 CDJDGQRYHDBSKC-UHFFFAOYSA-N 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- PPEKGEBBBBNZKS-UHFFFAOYSA-N Neosaxitoxin Natural products N=C1N(O)C(COC(=O)N)C2N=C(N)NC22C(O)(O)CCN21 PPEKGEBBBBNZKS-UHFFFAOYSA-N 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 241000687919 Rodinia Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PPEKGEBBBBNZKS-HGRQIUPRSA-N neosaxitoxin Chemical group N=C1N(O)[C@@H](COC(=O)N)[C@@H]2NC(=N)N[C@@]22C(O)(O)CCN21 PPEKGEBBBBNZKS-HGRQIUPRSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10153234 | 2010-02-10 | ||
| EP10153234.9 | 2010-02-10 | ||
| US31290310P | 2010-03-11 | 2010-03-11 | |
| US61/312,903 | 2010-03-11 | ||
| PCT/EP2011/051992 WO2011098539A1 (en) | 2010-02-10 | 2011-02-10 | Treatment of loss of sense of touch with saxitoxin derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016217143A Division JP2017081920A (ja) | 2010-02-10 | 2016-11-07 | サキシトキシン誘導体での触覚の喪失の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519653A JP2013519653A (ja) | 2013-05-30 |
| JP2013519653A5 true JP2013519653A5 (enExample) | 2014-03-13 |
| JP6112867B2 JP6112867B2 (ja) | 2017-04-12 |
Family
ID=43828310
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552401A Active JP6112867B2 (ja) | 2010-02-10 | 2011-02-10 | サキシトキシン誘導体での触覚の喪失の処置 |
| JP2016217143A Pending JP2017081920A (ja) | 2010-02-10 | 2016-11-07 | サキシトキシン誘導体での触覚の喪失の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016217143A Pending JP2017081920A (ja) | 2010-02-10 | 2016-11-07 | サキシトキシン誘導体での触覚の喪失の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9107925B2 (enExample) |
| EP (1) | EP2533785B1 (enExample) |
| JP (2) | JP6112867B2 (enExample) |
| CN (1) | CN102811722A (enExample) |
| ES (1) | ES2484315T3 (enExample) |
| WO (1) | WO2011098539A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| JP6112867B2 (ja) * | 2010-02-10 | 2017-04-12 | ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ | サキシトキシン誘導体での触覚の喪失の処置 |
| EP2638908A1 (en) * | 2012-03-16 | 2013-09-18 | Phytotox SpA | Paralytic Shellfish Poison |
| RU2015143665A (ru) * | 2013-03-15 | 2017-04-27 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Сочетанные препараты неосакситоксина для пролонгированной местной анестезии |
| EP3129381B1 (en) * | 2014-04-09 | 2020-11-04 | Siteone Therapeutics Inc. | 10',11'-modified saxitoxins useful for the treatment of pain |
| AU2016329201A1 (en) * | 2015-09-30 | 2018-04-26 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| GB201602576D0 (en) | 2016-02-12 | 2016-03-30 | Bergen Teknologioverforing As | Process |
| AU2018243463C1 (en) | 2017-03-29 | 2022-12-01 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| US11279706B2 (en) | 2017-03-29 | 2022-03-22 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| IL300626A (en) * | 2020-08-14 | 2023-04-01 | Siteone Therapeutics Inc | Ketone-free inhibitors of NAV1.7 for the treatment of pain |
| WO2022112887A1 (en) * | 2020-11-25 | 2022-06-02 | Algenis | Method of treating acute nociceptive pain in mammals |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284536C (zh) | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
| ES2401570T3 (es) | 2001-11-15 | 2013-04-22 | Phytotox Limited | Composiciones farmacéuticas que contienen 3,4-propinoperhidropurinas y usos de las mismas para bloquear la transmisión neuronal |
| CA2607206C (en) * | 2004-05-07 | 2016-06-14 | Phytotox Limited | Transdermal administration of phycotoxins |
| JP5047782B2 (ja) | 2004-05-07 | 2012-10-10 | ファイトトックス リミテッド | フィコトキシン及びその使用 |
| AU2005287511A1 (en) * | 2004-09-21 | 2006-03-30 | Wex Medical Limited | Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain |
| US20100075992A1 (en) | 2004-09-22 | 2010-03-25 | Laboratorios Del Dr. Esteve S.A. | Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain |
| ES2691411T3 (es) | 2006-03-27 | 2018-11-27 | Wex Medical Limited | Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| JP6112867B2 (ja) * | 2010-02-10 | 2017-04-12 | ファイトトックス リミテッドＰｈｙｔｏｔｏｘ Ｌｉｍｉｔｅｄ | サキシトキシン誘導体での触覚の喪失の処置 |
-
2011
- 2011-02-10 JP JP2012552401A patent/JP6112867B2/ja active Active
- 2011-02-10 CN CN2011800149701A patent/CN102811722A/zh active Pending
- 2011-02-10 WO PCT/EP2011/051992 patent/WO2011098539A1/en not_active Ceased
- 2011-02-10 EP EP11707610.9A patent/EP2533785B1/en active Active
- 2011-02-10 US US13/575,229 patent/US9107925B2/en active Active
- 2011-02-10 ES ES11707610.9T patent/ES2484315T3/es active Active
-
2015
- 2015-07-08 US US14/794,428 patent/US20160000793A1/en not_active Abandoned
-
2016
- 2016-11-07 JP JP2016217143A patent/JP2017081920A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519653A5 (enExample) | ||
| MY202837A (en) | Lipids for lipid nanoparticle delivery of active agents | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| JP2013542247A5 (enExample) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| KR20150013527A (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
| JP2009504763A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2015530382A5 (enExample) | ||
| RU2011146005A (ru) | Композиции для лечения воспаления и способы лечения воспаления | |
| JP2013522229A5 (enExample) | ||
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| JP2013518036A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| EP3791897A1 (en) | Hsp90 inhibitor drug conjugates | |
| JP2017513824A5 (enExample) | ||
| MY150682A (en) | Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| AR075626A1 (es) | Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso. | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies |